Biofrontera Inc.
BFRINasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $41.7M | $37.3M | $34.1M | $28.7M | $24.1M | $18.8M |
| Operating income | −$11.3M | −$17.2M | −$22.7M | −$18.6M | −$25.2M | −$9.6M |
| Net income | −$10.5M | −$17.8M | −$20.1M | −$640,000 | −$37.7M | −$11.0M |
| Total assets | $28.6M | $22.1M | $27.9M | $50.9M | $53.2M | $24.1M |
| Total liabilities | $18.1M | $17.7M | $23.1M | $27.0M | $41.9M | $18.3M |
| Equity | $10.5M | $4.4M | $4.8M | $23.9M | $11.3M | $5.8M |
| EPS (diluted) | $-1.04 | $-3.22 | $-13.02 | $-0.61 | $-4.28 | — |
| Shares out. | 8.9M | 5.1M | 26.7M | 17.1M | 17.1M | 8.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −27.2%
- Net margin
- −25.3%
- Return on equity
- −100.5%
- Return on assets
- −36.9%
- Return on capital (ROCE)
- −68.1%
- Liabilities / assets
- 63.3%
- Debt / equity
- 1.73×
- Book value / share
- $1.18
- Revenue growth (YoY)
- 11.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -15.24distress
- Accruals / assets
- 9.9%moderate
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 3 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Apr 1, 2022
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
FDA-approved drugs
openFDA · most recent- AMELUZMay 10, 2016
- AKTIPAKNov 27, 2000
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2024-03-19Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).
- Phase 2Active Not Recruitingreadout ~2025-08-22Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
- Phase 3Active Not Recruitingreadout ~2025-09-03Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Rosalind Advisors, Inc.Passive (13G)Feb 11, 2026
- Hirschman OrinPassive (13G)Jan 28, 2026
- Deutsche Balaton AktiengesellschaftActivist (13D)Sep 19, 2025
- Lytton Laurence WPassive (13G)May 15, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 84,396 | 1.0 | +10.5% |
| Apr 30, 2026 | 76,357 | 1.0 | +5.3% |
| Apr 15, 2026 | 72,497 | 1.0 | -75.5% |
| Mar 31, 2026 | 295,934 | 2.4 | +69.5% |
| Mar 13, 2026 | 174,589 | 1.6 | +15.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 14, 2026
- Results of operationsMar 19, 2026
- Regulation FD disclosureMar 9, 2026
- Other material eventFeb 26, 2026
- Regulation FD disclosureFeb 9, 2026
- Results of operationsJan 13, 2026
- Delisting / listing-standard noticeJan 7, 2026
- Results of operationsNov 13, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.